BCL2 and myelofibrosis: Notably, this is exemplified by studies of ruxolitinib in combination with bromodomain inhibition or inhibition of the anti-apoptotic Bcl2 family members that are showing promising results in clinical studies in myelofibrosis patients [53–55].